Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml
Download PDF
Z Gastroenterol 2025; 63(10): 1020-1022
DOI: 10.1055/a-2537-1181
DOI: 10.1055/a-2537-1181
Über den Tellerrand
Varizella-Zoster-Virus
Authors
Das Varizella-Zoster-Virus ist ein Virus aus der Gruppe der humanen Herpesviren. In der Manifestation der Primärinfektion ruft das Virus die Varizellen (Windpocken) hervor und begibt sich im Anschluss an die aktive Replikation in neuronalen Zellen in den Zustand der lebenslangen Latenz. Die latenten Virusgenome können bei Nachlassen der Immunität Rezidive hervorrufen, von denen der Zoster die wichtigste Erscheinungsform ist.
Publication History
Article published online:
08 October 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literatur
- 1 Rieck T, Feig M, An der Heiden M. et al. Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Euro Surveill 2017; 22
- 2 Hillebrand K, Bricout H, Schulze-Rath R. et al. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect 2015; 70: 178-186
- 3 Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266-2267
- 4 Forbes HJ, Bhaskaran K, Thomas SL. et al. Quantification of risk factors for herpes zoster: Population based case-control study. BMJ 2014; 348: g2911
- 5 Eyting M, Xie M, Michalik F. et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature 2025; 641: 438-446
- 6 Taquet M, Dercon Q, Todd JA. et al. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med 2024; 30: 2777-2781
- 7 Lee S, Lee K, Oh J. et al. Live zoster vaccination and cardiovascular outcomes: A nationwide, south korean study. Eur Heart J 2025; ehaf230
- 8 Orru S, Bierbaum S, Enk A. et al. Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020. Euro Surveill 2023; 28: 2300261
- 9 Siedler A, Koch J, Garbe E. et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the german standing committee on vaccination (stiko) at the robert koch institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 352-376
- 10 Strezova A, Diez-Domingo J, Al Shawafi K. et al. Zoster-049 Study, G. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022; 9: ofac485